Lumos Diagnostics Holdings Limited (ASX:LDX)

Market Cap	86.48M -33.3%
Revenue (ttm)	19.07M +6.4%
Net Income	-7.16M
EPS	-0.01
Shares Out	971.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	543,906
Open	0.0880
Previous Close	0.0860
Day's Range	0.0850 - 0.0890
52-Week Range	0.0760 - 0.3300
Beta	0.46
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 20, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LDX

Financial Performance

In fiscal year 2026, ASX:LDX's revenue was $13.19 million, an increase of 6.39% compared to the previous year's $12.40 million. Losses were -$4.95 million, -31.06% less than in 2025.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error